Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-06-29T23:31:00.222Z Has data issue: false hasContentIssue false
  • English
  • Français

Mouse or man? Which are pertussis vaccines to protect?

Published online by Cambridge University Press:  15 May 2009

N. W. Preston  and
T. N. Stanbridge
N. W. Preston
Affiliation:
Department of Bacteriology and Virology, University of Manchester, Manchester M13 9PT
T. N. Stanbridge
Affiliation:
Department of Bacteriology and Virology, University of Manchester, Manchester M13 9PT
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Type 1 strains of Bordetella pertussis can infect mouse brain and have been recovered as type 1 organisms after death. When introduced into the naso-pharynx of the marmoset, they immediately acquired agglutinogen 2 or 3, and the resulting type 1,2 or 1,3 infection persisted for many weeks.

As in the child, agglutinogens 2 and/or 3 appear to be essential for infection of the marmoset, whereas they are quite unnecessary in mouse brain. A vaccine (extract or whole cell) containing agglutinogen 1 may be sufficient to pass the mouse protection test but it may fail to immunize children. The mouse test is inadequate even for the screening of such extracts.

Type
Research Article
Information
Journal of Hygiene , Volume 76 , Issue 2 , April 1976 , pp. 249 - 256
Copyright
Copyright © Cambridge University Press 1976

References

REFERENCES

Andersen, E. K. (1952). Some observations made during experiments on mice inoculated with H. pertussis. Acta pathologica et microbiologica scandinavica 31, 546.CrossRefGoogle ScholarPubMed
Cameron, J. (1967). Variation in Bordetella pertussis. Journal of Pathology and Bacteriology 94, 367.CrossRefGoogle ScholarPubMed
Dolby, J. M. & Bronne-Shanbury, C. J. (1975). The use of spheroplast-derived strains to differentiate between Bordetella pertussis heat-labile agglutinogens and protective antigen for mice. Journal of Biological Standardization 3, 89.CrossRefGoogle ScholarPubMed
Dolby, J. M. & Stephens, S. (1973). Pertussis antibodies in the sera of children exposed to Bordetella pertussis by vaccination or infection. Journal of Hygiene 71, 193.CrossRefGoogle ScholarPubMed
Eldering, G., Holwerda, J. & Baker, J. (1966). Bordetella pertussis culture having only species factor 1. Journal of Bacteriology 91, 1759.CrossRefGoogle ScholarPubMed
Kendrick, P. L., Eldering, G., Dixon, M. K. & Misner, J. (1947). Mouse protection tests in the study of pertussis vaccine. A comparative series using the intracerebral route for challenge. American Journal of Public Health 37, 803.CrossRefGoogle Scholar
Medical Research Council (1959). Vaccination against whooping-cough. British Medical Journal i, 994.Google Scholar
Nakase, Y., Takatsu, K. & Kasuga, T. (1969). Antigenic structure and phase variation in Bordetella pertussis. Japanese Journal of Microbiology 13, 283.CrossRefGoogle ScholarPubMed
Perkins, F. T. (1969). Vaccination against whooping-cough. British Medical Journal iv, 429.CrossRefGoogle Scholar
Pillemer, L., Blum, L. & Lepow, I. H. (1954). Protective antigen of Haemophilus pertussis. Lancet i, 1257.CrossRefGoogle Scholar
Preston, N. W. (1965). Effectiveness of pertussis vaccines. British Medical Journal ii, 11.CrossRefGoogle Scholar
Preston, N. W. (1966). Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice. Journal of Pathology and Bacteriology 91, 173.CrossRefGoogle ScholarPubMed
Preston, N. W. (1975 a). What makes a good pertussis vaccine? Progress in Drug Research 19, 341.Google ScholarPubMed
Preston, N. W. (1975 b). Vaccine composition in relation to antigenic variation of the microbe: is pertussis unique? Progress in Drug Research 19, 347.Google Scholar
Preston, N. W. & Evans, P. (1963). Type-specific immunity against intra-cerebral pertussis infection in mice. Nature, London 197, 508.CrossRefGoogle Scholar
Preston, N. W. & Stanbridge, T. N. (1972). Efficacy of pertussis vaccines: a brighter horizon. British Medical Journal iii, 448.CrossRefGoogle Scholar
Preston, N. W. & TePunga, W. A. Punga, W. A. (1959). The relation between agglutinin production by pertussis vaccines and their immunising potency in mice. Journal of Pathology and Bacteriology 78, 209.CrossRefGoogle ScholarPubMed
Public Health Laboratory Service (1969). Efficacy of whooping-cough vaccines used in the United Kingdom before 1968. British Medical Journal iv, 329.Google Scholar
Ross, R. F. & Munoz, J. (1971). Antigens of Bordetella pertussis: separation of agglutinogen 1 and mouse-protective antigen. Infection and Immunity 3, 243.CrossRefGoogle ScholarPubMed
Stanbridge, T. N. & Preston, N. W. (1974 a). Experimental pertussis infection in the marmoset: type specificity of active immunity. Journal of Hygiene 72, 213.CrossRefGoogle ScholarPubMed
Stanbridge, T. N. & Preston, N. W. (1974 b).Variation of serotype in strains of Bordetella pertussis. Journal of Hygiene 73, 305.CrossRefGoogle ScholarPubMed
Standfast, A. F. B. (1958). Some factors influencing the virulence for mice of Bordetella pertussis by the intracerebral route. Immunology 1, 123.Google ScholarPubMed